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Aims Cardiovascular events remain the leading cause of death in Western world. Atherosclerosis is the most common under-
lying complication driven by low-density lipoproteins (LDL) disturbing vascular integrity. Carbamylation of lysine resi-
dues, occurring primarily in the presence of chronic kidney disease (CKD), may affect functional properties of
lipoproteins; however, its effect on endothelial function is unknown.
Methods
and results
Low-density lipoprotein from healthy donors was isolated and carbamylated. Vascular reactivity after treatment with
native LDL (nLDL) or carbamylated LDL (cLDL) was examined in organ chambers for isometric tension recording
using aortic rings of wild-type or lectin-like-oxidized LDL receptor-1 (LOX-1) transgenic mice. Reactive oxygen
species (ROS) and nitric oxide (NO) production were determined using electron spin resonance spectroscopy. The
effect of LDL-carbamyl-lysine levels on cardiovascular outcomes was determined in patients with CKD during a
median follow-up of 4.7 years. Carbamylated LDL impaired endothelium-dependent relaxation to acetylcholine or
calcium-ionophore A23187, but not endothelium-independent relaxation to sodium nitroprusside. In contrast, nLDL
had no effect. Carbamylated LDL enhanced aortic ROS production by activating NADPH-oxidase. Carbamylated LDL
stimulated endothelial NO synthase (eNOS) uncoupling at least partially by promoting S-glutathionylation of eNOS.
Carbamylated LDL-induced endothelial dysfunction was enhanced in LOX-1 transgenic mice. In patients with CKD,
LDL-carbamyl-lysine levels were significant predictors for cardiovascular events and all-cause mortality.
Conclusions Carbamylation of LDL induces endothelial dysfunction via LOX-1 activation and increased ROS production leading to
eNOS uncoupling. This indicates a novel mechanism in the pathogenesis of atherosclerotic disease which may be patho-
genic and prognostic in patients with CKD and high plasma levels of cLDL.
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Introduction
Cardiovascular disease is the leading cause of death in industrialized
countries. In the USA, cardiac and cerebrovascular disease ac-
counted for almost one-third of all deaths in 2006.1 Although
mortality declined during the last years, the morbidity associated
with atherosclerosis and its consequences remains high, particularly
in patients with diabetes and/or chronic kidney disease (CKD).2,3
Besides other cardiovascular risk factors such as hypertension,
obesity, diabetes, and smoking,4 hypercholesterolaemia is strongly
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associated with the incidence of cardiovascular events.5 There is a
growing body of evidence indicating that lipid-lowering therapy con-
siderably reduces cardiovascular event rate after the occurrence of a
first event as well as in primary prevention.6,7 Despite of such bene-
ficial effects, the incidence of cardiovascular events remains high.
Notably, half of all the patients with a myocardial infarction display
normal plasma lipid levels,8 and biomarkers such as C-reactive
protein seem to be stronger predictors of cardiovascular events
than low-density lipoprotein (LDL)-cholesterol plasma levels.9
Recent evidence suggests that not only the absolute LDL-cholesterol
plasma level, but functional properties of the lipoproteins may play an
important role in the pathogenesis of atherosclerosis.10 It is well
established that posttranslational modifications of LDL particles
such as oxidation (oxLDL) crucially deteriorate its functional proper-
ties leading to a pro-atherogenic phenotype.11,12 Plasma levels of
oxLDL correlate well with the vulnerability of atherosclerotic
lesions13 and are strong predictors for cardiovascular events.14,15
Carbamylation of LDL-cholesterol was recently discovered as a
novel modification of this lipoprotein in patients with CKD.16,17
Urea-derived cyanate induces the carbamylation of lysine residues
leading to the formation of 1-carbamyl-lysine (homocitrulline).18
Additionally, myeloperoxidase catalysed lipoprotein carbamylation
was identified as an alternative for cyanate-mediated protein carba-
mylation, which is particularly important in smokers.19
Recent data suggest that carbamylated LDL (cLDL) may promote
the formation of atherosclerotic lesions.20 However, the underlying
mechanisms, in particular the role of cLDL in endothelial dysfunction
as a first critical step in the pathogenesis of atherosclerosis, have not
been well understood yet. We therefore conducted the present
study to examine the effect of cLDL on endothelial function.
Methods
Detailed description of methods is presented on Supplementary material
online.
Detection of reactive oxygen species and nitric
oxide using electron spin resonance
spectroscopy
Production of ROS in aortic rings, human aortic endothelial cells
(HAECs), and whole blood was measured using electron spin resonance
(ESR) spectroscopy, as described previously.21 Details are described in
Supplementary material online.
Statistics
All data are expressed as means+ SEM. Statistical comparisons were
performed with Student’s t-test for simple comparisons between two
groups. For multiple comparisons, results were analysed by one-way
ANOVA followed by Tukey’s post hoc test. A value of P, 0.05 was con-
sidered statistically significant.
In the clinical study, patients were stratified into two categories
according to the median of carbamylated-lysine in LDL (≤ 28.1 or.
28.1 mg/mg LDL protein). Continuous data are presented as means+
SD when normally distributed or as median and inter-quartile range for
variables with skeweddistribution. Categorical data arepresented as per-
centage. Statistical differences between continuous variables were deter-
mined using the one-way ANOVA or Kruskal–Wallis test or x2 test for
categorical variables. To examine the effect of LDL-carbamyl-lysine
levels on all-cause mortality and cardiovascular events, Kaplan–Meier
curves were built for LDL-carbamyl-lysine levels divided into two cat-
egories at median. Differences between both groups were analysed by
using the Log-rank test. Moreover, Cox-proportional hazard models
were built, including LDL-carbamyl-lysine levels in a crude model as
well as adjusted for age, sex, diabetes mellitus, pre-existing coronary
artery disease, hs-C reactive protein, and eGFR.
All P-values were adjusted for multiple comparisons where appropri-
ate. All statistical calculations were carried out using the PRISM software
(GraphPad Prism for MacOSX, 5.0d) or SPSS software (Version 20.0).
Results
Low-density lipoprotein carbamylation
Immediately after ex vivo carbamylation, the degree of carbamoyl-
DL-lysine was determined. Carbamylation of LDL yielded 27.4+
0.9 nmol/mg carbamoyl-DL-lysine, whereas no carbamoyl-DL-lysine
was detectable in native LDL preparations (Figure 1A and B).
Neither cLDL nor LDL preparations contained relevant lipid perox-
idation (Figure 1C).
Carbamylated low-density lipoprotein
impairs endothelium-dependent
relaxation
To determine the effect of LDL carbamylation on endothelial func-
tion, organ chamber experiments using aortic rings from wild-type
(WT) C57BL/6J mice were performed. Treatment with cLDL
inhibited acetylcholine-induced endothelium-dependent relaxation
(P ¼ 0.002), whereas nLDL did not affect the response (P ¼ 0.99)
(Figure 2A). Neither cLDL nor nLDL altered vascular contraction
of aortic rings in the presence of norepinephrine (Figure 2B).
Similar to acetylcholine, endothelium-dependent relaxation to the
calcium-ionophore A23187 was impaired after cLDL treatment
(P, 0.001; Figure 2C). In contrast, relaxations to sodium nitroprus-
side remained unaltered by cLDL (P ¼ 0.92, Figure 2D), indicating
that cLDL inhibits endothelium-dependent, but not endothelium-
independent relaxations to both receptor-dependent and receptor-
independent agonists.
Carbamylated low-density lipoprotein
induces endothelial reactive oxygen
species production
To gain further insights into the mechanism of cLDL-induced endothe-
lial dysfunction (ED), we tested the vascular reactivity of aortic rings in
the presence of indomethacin, an inhibitor of cyclooxygenase. Indo-
methacin did not alter the inhibitory effect of cLDL on vasodilation
ruling out the involvement of vasoactive prostaglandins as a cause of
the impaired endothelium-dependent relaxations (Figure 3A).
Enhanced production of reactive oxygen species (ROS) is known
to reduce the bioavailability of endothelium-derived nitric oxide
(NO) leading to ED.22 Addition of the ROS scavengers PEG-SOD/
PEG-catalase restored endothelium-dependent relaxation to acetyl-
choline in cLDL-treated aortic rings (P, 0.001; Figure 3B), indicating
apivotal roleofROS incLDL-inducedED.Accordingly, in aortic rings,
cLDL significantly induced aortic ROS production (P, 0.01), while
nLDL had no effect (P ¼ 0.93; Figure 3C and D).
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Carbamylated low-density lipoprotein
induces uncoupling of endothelial nitric
oxide synthase
Human aortic endothelial cells were incubated with cLDL to quantify
endothelial NO production. Carbamylated LDL, but not nLDL, sig-
nificantly reduced basal NO production in HAEC (Figure 4A and B)
confirming the functional data of the organ chamber experiments.
Enzymatic activity of endothelial NO synthase (eNOS) is modu-
lated by phosphorylation at different regulatory sites.23 Carbamy-
lated LDL treatment reduced eNOS phosphorylation at the
activating residue Ser1177 and concomitantly enhanced phosphoryl-
ation of eNOS at the inhibitory site Thr495 (Figure 4C–D). Thus,
inhibition of endothelium-dependent relaxation through cLDL is in
part mediated by a reduced activity of eNOS.
Since cLDL stimulated ROS production in aortic rings, we analysed
whether the endothelium is the prevailing source for ROS produc-
tion in response to the modified lipoproteins. Carbamylated LDL
induced production of ROS in HAEC, whereas nLDL had no effect
(P ¼ 0.016, Figure 4E).
Besides its role as NO producing enzyme, eNOS can act as a
source of ROS when its dimer is uncoupled.24 Therefore, we quanti-
fied eNOS uncoupling using a western blot technique. Carbamylated
LDL increased the ratio of monomeric to total eNOS compared with
untreated cells 10 min after stimulation, while nLDL did not affect
this ratio (Figure 4F).
Figure 1 (A) Representative amino acid analysis of native and carbamylated low-density lipoproteins after ex vivo carbamylation by HPLC, arrow
indicates carbamoyl-DL-lysine peak. (B) Carbamoyl-DL-lysine content in low-density lipoprotein preparation after ex vivo carbamylation (n ¼ 10). (C)
Malondialdehyde content of low-density lipoprotein preparations determined by TBARS assay (n ¼ 10 per group). Results are presented as
means+ SEM.
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Figure 2 (A) Endothelium-dependent relaxations to acetylcholine in aortic rings treated with native low-density lipoprotein or carbamylated low-
density lipoprotein (100 mg/mL;n ¼ 8pergroup)andcalculatedAUC.(B)Contractions tonorepinephrin inaortic rings (n ¼ 6pergroup)andcalculated
AUC. (C) Endothelium-dependent relaxations to A23187 (n ¼ 6 per group) and calculated AUC. (D) Endothelium-independent relaxations to sodium
nitroprusside (n ¼ 5 per group) and calculated AUC. Results are presented as means+SE and P-values were adjusted for multiple comparisons where
appropriate.
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S-glutathionylation of eNOS may induce eNOS uncoupling.25
Therefore, we visualized co-localization of S-glutathionylation
and eNOS in HAEC treated with nLDL, cLDL, and 1,3-bis
(2-chloroethyl)-1-nitrosourea (BCNU), an inhibitor of glutathione
reductase, by immunofluorescence microcopy (Figure 4G).
Carbamylated LDL, but not nLDL, up-regulated endothelial
S-glutathionylation, which co-localized with eNOS comparable
with cells treated with BCNU. Thus, S-glutathionylation of eNOS
may be at least partially responsible for cLDL-induced eNOS
uncoupling.
Figure 3 (A) Endothelium-dependent relaxations to acetylcholine in aortic rings+ indomethacin (n ¼ 5 per group) and calculated AUC. (B)
Endothelium-dependent relaxations to acetylcholine in aortic rings+PEG-SOD/PEG-catalase (n ¼ 7 per group) and calculated AUC. (C) Reactive
oxygen species production in aortic rings treated with native low-density lipoprotein or carbamylated low-density lipoprotein (100 mg/mL, 1 h,
n ¼ 10 per group) determined by electron spin resonance spectroscopy. (D) Representative electron spin resonance spectra of reactive oxygen
species production in aortic rings. Results are presented as means+ SE and P-values were adjusted for multiple comparisons where appropriate.
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Figure 4 (A) Nitric oxide production in human aortic endothelial cells treated with native low-density lipoprotein or carbamylated low-density
lipoprotein (100 mg/mL, 1 h, n ¼ 4 per group) determined by electron spin resonance spectroscopy. (B) Representative electron spin resonance
spectra of nitric oxide production in human aortic endothelial cells and human aortic endothelial cells treated with L-NAME (0.3 mM) as a
control. (C ) Endothelial nitric oxide synthase-activating phosphorylation at Ser1177 in human aortic endothelial cells treated with native low-density
lipoprotein or carbamylated low-density lipoprotein (100 mg/mL, 10 min, n ¼ 5 per group). (D) Endothelial nitric oxide synthase -inhibiting phos-
phorylation at Thr495 in human aortic endothelial cells treated with native low-density lipoprotein or carbamylated low-density lipoprotein
(100 mg/mL, 10 min, n ¼ 5 per group). (E) Reactive oxygen species production in human aortic endothelial cells treated with native low-density
lipoprotein or carbamylated low-density lipoprotein (100 mg/mL, 1 h, n ¼ 4 per group) determined by electron spin resonance spectroscopy.
(F ) Endothelial nitric oxide synthase uncoupling in human aortic endothelial cells treated with native low-density lipoprotein or carbamylated low-
density lipoprotein (100 mg/mL, 10 min, n ¼ 6 per group) determined by western blot analysis quantifying endothelial nitric oxide synthase
monomer/total endothelial nitric oxide synthase, H2O2 (5 mmol/L) served as a control. (G) Immunofluorescent staining for endothelial nitric
oxide synthase (green) and S-glutathionylation (red). Nuclei are stained with 4′,6-diamidino-2-phenylindole (blue). Overlay is performed in
human aortic endothelial cells treated with native low-density lipoprotein, carbamylated low-density lipoprotein (100 mg/mL), or
1,3-bis(2-chloroethyl)-1-nitrosourea (25 and 80 mM) as a control for 4 h. Images are representative for three independent experiments. Results
are presented as means+ SE and P-values were adjusted for multiple comparisons where appropriate.
T. Speer et al.3026
Lectin-like-oxidized low-density
lipoprotein receptor-1 mediates
carbamylated low-density
lipoprotein-induced ED
Recent evidence suggests that cLDLmay interactwith the endothelial
lectin-like-oxidized LDL receptor-1 (LOX-1).26 Lectin-like-oxidized
LDL receptor-1 is known to mediate adverse endothelial effects of
oxLDL and other agents by inducing oxidative stress.27 To examine
the impact of LOX-1 on cLDL-induced ED, transgenic mice over-
expressing endothelial LOX-1 were generated (LOX-1/Tg) and
organ chamber experiments using aortic rings from these mice
were performed. Under control conditions, endothelium-dependent
relaxation in response to acetylcholine did not differ between WT
and LOX-1/Tg mice. In contrast, the inhibitory effect of cLDL on vaso-
dilation was significantly enhanced in LOX-1/Tg mice when compared
with WT control mice (Figure 5A).
To confirm LOX-1 as the receptor-mediating cLDL-induced ED,
we quantified the effect of cLDL on endothelial NO production in
the presence or absence of siRNA targeting LOX-1. Silencing of
LOX-1 abrogated the inhibitory effect of cLDL on endothelial NO
release (P, 0.001), whereas siRNA targeting LOX-1 did not
change the effect of nLDL on endothelial NO production (P ¼
0.16; Figure 5B).
Accordingly, in vivo, 24 h after injection of cLDL or nLDL into WT
and LOX-1/Tg mice, cLDL-induced ROS production in whole blood,
and in aortic rings was further augmented in LOX-1/Tg mice when
compared with WT animals (Figures 5C and D). These in vivo findings
confirm our results obtained in vitro in HAEC and in ex vivo-treated
aortic rings.
Lectin-like-oxidized low-density
lipoprotein receptor-1 stimulated
activation of NADPH-oxidase
We next aimed at determining the molecular mechanisms by which
activation of LOX-1 by cLDL increases endothelial ROS production.
Since LOX-1 activation has been shown to increase endothelial
NADPH-oxidase activity,28 we measured endothelial ROS produc-
tion in response to cLDL in the presence of the NADPH-oxidase
inhibitor diphenylene iodinium (DPI) or captopril. Indeed, cLDL-
induced endothelial ROS production was almost completely pre-
vented in the presence of DPI or captopril, indicating a crucial role
of NADPH-oxidase for cLDL-induced ROS production (Figure 6A).
Moreover, we studied the role of different mitogen-activated
protein kinases (MAPK), which have been documented as down-
stream factors of LOX-1,28 in mediating the adverse endothelial
effects of cLDL. In these experiments, we found that the inhibitor
of p38-MAPK SB202190 significantly attenuated the effect of cLDL
on endothelial ROS production (Figure 6B). We also observed that
cLDL substantially increased phosphorylation of p38-MAPK in
HAEC in a time-dependent manner (Figure6C). These results indicate
that the effectsof cLDLonendothelialROSproductionmayat least in
part be mediated by LOX-1-induced p38-phosphorylation.
It has been reported that several amino acids may attenuate carba-
mylation of albumin.29 Therefore, we determined ROS of HAEC
treated with LDL, which was carbamylated in the presence of distinct
amino acids (Figure6D). Notably, L-arginine, L-cysteine, and L-histidine
presentduring incubation of LDLwith potassium cyanate significantly
reduced the effect of such prepared cLDL on endothelial ROS
production.
Carbamylated low-density lipoprotein in
patients with chronic kidney disease
To examine the relevance of these findings in patients, we quantified
the number of post-translationally carbamylated-lysine residues in
LDL isolated from healthy subjects and patients with CKD by using
matrix-assisted laser desorption/ionization time-of-flight mass-
spectrometry (Figure 7A). In ex vivo cLDL, which was used for the
experiments in the present study, we could detect posttranslational
carbamylation of 34 lysine residues. Notably, in CKD patients an
average of 54+ 4 lysine residues of LDL was carbamylated,
whereas no carbamylated sites were detected in LDL isolated from
healthy control subjects.
Notably, in HAEC treated with isolated LDL from the same
patients and healthy controls, we observed a significant reduction
of endothelial NO production after incubation with LDL from
CKD patients (P, 0.001) when compared with LDL from healthy
subjects (Figure 7B).
Finally, to examine whether carbamylation of LDL may affect CV
outcome in patients with CKD, we isolated LDL from 96 patients
with proven CKD and determined the concentration of carbamyl-
lysine in the LDL fractions. The baseline characteristics of the
study cohort are shown in Supplementary material online, Table S1.
The cohort was divided into two categories at the median of
LDL-carbamyl-lysine levels. Patients with LDL-carbamyl-lysine
.28.1 mg/mg LDL protein had a significantly higher all-cause
mortality (P ¼ 0.002, Figure 7C) as well as a significantly shorter
cardiovascular events (CVE)-free survival (P, 0.001, Figure 7D).
Notably, even after adjustments for potential confounders,
LDL-carbamyl-lysine remained a powerful predictor for all-cause
mortality and CVE in Cox-proportional hazard models (Supplemen-
tary material online, Table S2).
Discussion
This study demonstrates for the first time that cLDL induces endo-
thelial dysfunction via LOX-1 activation leading to p38-MAPK and
NADPH-oxidase activation, eNOS uncoupling, increased endothe-
lial ROS production, reduced NO bioavailability, and finally impaired
endothelium-dependent vasodilation. Moreover, in patients with
CKD, carbamyl-lysine levels in LDL were associated with increased
cardiovascular events and all-cause mortality.
Nitric oxide is a key regulator of endothelial function since the free
radical does not only regulate vascular tone, but also prevents endo-
thelial inflammatory and pro-coagulatory pathways.30 Not surpris-
ingly, endothelial dysfunction represents a crucial initial step in the
pathogenesis of atherosclerosis and predicts future cardiovascular
events.31 Endothelial dysfunction is mainly characterized by a dysba-
lance between the production of NO and that of ROS resulting in a
vicious circle, as ROS react with NO to form peroxynitrite leading
to a further reduction in NO bioavailability and posttranscriptional
modification of cellular proteins.30,31
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Figure 5 (A) Endothelial-dependent relaxations to acetylcholine in aortic rings from wild-type and endothelial lectin-like-oxidized low-density
lipoprotein receptor-1/Tg mice (n ¼ 6 per group) and calculated AUC. (B) Nitric oxide production in human aortic endothelial cells stimulated
with native low-density lipoprotein or carbamylated low-density lipoprotein after silencing of lectin-like-oxidized low-density lipoprotein
receptor-1 (n ¼ 6 per group). NFS, nanoparticle forming solution. Reactive oxygen species production in whole blood (C) and aortic rings (D)
of wild-type and lectin-like-oxidized low-density lipoprotein receptor-1/Tg mice 24 h after injection of native low-density lipoprotein or carbamy-
lated low-density lipoprotein (15 mg/kg, n ¼ 4 per group) determined by electron spin resonance spectroscopy. Results are presented as
mean+ SE and P-values were adjusted for multiple comparisons where appropriate.
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Lipoproteins are important regulators of endothelial function.
Whereas high-density lipoprotein (HDL) mainly exerts protective
effects,32 LDL promotes endothelial dysfunction and in turn athero-
sclerosis once it has been modified by ROS induced oxidation.33 Re-
cently, novel forms of lipoprotein modification have been described.
Urea- or myeloperoxide-driven carbamylation of lipoprotein lysine
residues indeed impairs the functional integrity of HDL and LDL par-
ticles.16,19 Of note, serum levels of carbamylated proteins and in par-
ticular lipoproteins are elevated in patients with coronary artery
disease and particularly in those with CKD.16,17,19
In the present study, LDL isolated from healthy donors was
carbamylated ex vivo using potassium cyanate in order to generate
well-defined experimental conditions. Notably, the numberof carba-
mylation sites in LDL from CKD patients was even higher when
compared with the ex vivo cLDL used for the experiments. This
underscores the clinical relevance of the present findings and we
assume an enzymatic carbamylation process in vivo. The detrimental
effects of cLDL observed in this study may well occur in such patients
as well as in those with a high myeloperoxidase activity.
In organ chamber experiments using aortic rings from C57Bl/6J
mice, we observed that cLDL impaired acetylcholine- and calcium-
ionophore induced endothelium-dependent relaxation, while nLDL
did not affect vascular reactivity. Thus, the effect is specific for the
carbamylated form of the lipoprotein and must involve a mechanism
other than the muscarinic receptor and its signal transduction, since
the response to the calcium-ionophore was equally affected.
Because the relaxation to the NO donor sodium nitroprusside was
not affected by cLDL, the latter specifically impairs the function of
the endothelium, but not the vasodilating capacity of vascular
smooth muscle cells. The effect of cLDL on vascular relaxation was
Figure6 (A)Reactiveoxygen speciesproduction inhumanaortic endothelial cells treatedwith carbamylated low-density lipoprotein (100 mg/mL,
1 h) after preincubation with the NADPH-oxidase inhibitor diphenylene iodinium (5 mM, 30 min) or captopril (10 mM; n ¼ 3–5 per group). (B)
Reactive oxygen species production in human aortic endothelial cells treated with carbamylated low-density lipoprotein (100 mg/mL, 1 h) after pre-
incubation with the p38 mitogen-activated protein kinase inhibitor SB202190 (5 mM, 30 min; n ¼ 3–5 per group). (C) Time course of phosphor-
ylation of p38 mitogen-activated protein kinase at Thr180/Tyr182 in human aortic endothelial cells after treatment with carbamylated low-density
lipoprotein (100 mg/mL, n ¼ 4). (D) Reactive oxygen species production in human aortic endothelial cells treated with carbamylated low-density
lipoprotein (100 mg/mL, 1 h) carbamylated in the presence of amino acids (each 10 mM, n ¼ 4 per group) as indicated. **P, 0.01 and
***P, 0.001 for comparison with carbamylated low-density lipoprotein alone. Results are presented as means+ SE and P-values were adjusted
for multiple comparisons where appropriate.
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comparable with that of oxLDL, indicating that different modifications
ofLDLcan exert a similar effectonvascular functionpossibly via similar
pathways.12 Moreover, the findings that LDL from healthy subjects did
not altered endothelium-dependent vasodilation as well as endothelial
NOandROSproduction suggests that the effect ofLDLon endothelial
function ismainlydeterminedbymodificationsof theLDLparticle such
as carbamylation or oxidation.34,35
A recent study revealed that LOX-1 may be the receptor predom-
inantly mediating cellular effects of cLDL at least in endothelial cells.26
Thus, the effect of cLDL on endothelium-dependent relaxation to
acetylcholine was determined in aortic rings from transgenic mice
exhibiting endothelium-specific overexpression of LOX-1. Endothe-
lial dysfunction in response to cLDL was indeed enhanced in LOX-1/
Tg, but not in WT mice. In contrast, nLDL did not affect the relaxation
of aortic rings from LOX-1/Tg or WT mice. The involvement of the
LOX-1 receptor was confirmed using genetic silencing in HAEC,
since down-regulation of LOX-1 by siRNA prevented the cLDL-
induced inhibition of NO production in HAEC. Notably, in vivo
experiments clearly confirmed the role of LOX-1 in mediating the
effect of cLDL on ED. This is of relevance since LOX-1 is crucially
involved in atherosclerosis and highly expressed in human athero-
sclerotic lesions.36 Furthermore, activation of LOX-1 with oxLDL
has been documented to enhance endothelial oxidative stress and in-
flammatory activation.27 Therefore, the detrimental effects of cLDL
may not only be important for endothelial dysfunction, but also for
the development of atherosclerotic lesions.
The specific activation pattern of the endothelial LOX-1 receptor
by cLDL together with the absence of any effect of the cLDL on
Figure 7 (A) Quantification of carbamylated sites in low-density lipoprotein isolated from chronic kidney disease patients and healthy subjects
(n ¼ 9 per group). The left bar represents the number of carbamylation sites in low-density lipoprotein carbamylated ex vivo by incubation with po-
tassium cyanate for 4 h as a positive control. Each bar represents an individual subject. (B) Effect of low-density lipoprotein (100 mg/mL, 1 h) isolated
from the same patients as in (A) on endothelial nitric oxide production in human aortic endothelial cells (n ¼ 9 per group). (C) Kaplan–Meier curve
forall-cause mortality and (D) cardiovascular events of patients with chronickidneydisease (n ¼ 96)divided into two categories according to median
low-density lipoprotein-carbamyl-lysine levels. Results are presented as means+ SE and P-values were adjusted for multiple comparisons where
appropriate.
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vascular smooth muscle cells suggest that either NO production
or NO bioavailability or, alternatively, vasoconstrictor prostaglan-
dins must be involved in cLDL-induced endothelial dysfunction.
However, unselective inhibition of cyclooxygenase using indometh-
acin did not alter endothelium-dependent relaxations to acetylcho-
line in response to cLDL.
Contrarily, scavenging of ROS using PEG-SOD /PEG-catalase pre-
vented cLDL-induced endothelial dysfunction. Therefore, cLDL
must stimulate the endothelial production of ROS. Consistent with
this interpretation, cLDL induced ROS production both in aortic
rings and in cultured HAEC. These findings are in line with a recent
studydemonstrating that cLDL inducesoxidative stress in endothelial
progenitor cells.37
Reactiveoxygen speciesproduction inendothelial cells mayorigin-
ate from NADPH oxidases, mitochondria, or eNOS itself if it is
uncoupled. The data generated with the NADPH-oxidase inhibitor
DPI indicate that activation of NADPH-oxidase occurring down-
stream of the MAPK p38 may contribute to ROS formation in re-
sponse to cLDL.
Several agents are known to induce eNOS uncoupling.22,24
Inmarkedcontrast to dimeric eNOS which oxidizes L-arginine result-
ing in the formation of L-citrulline and NO, uncoupled eNOS loses its
ability to produce NO and instead generates ROS. We observed that
cLDL leads to eNOS uncoupling as indicated by a higher ratio of
monomeric to total eNOS. Recently, S-glutathionylation of eNOS
has been shown to induce eNOS uncoupling.25 Here, we found
that cLDL up-regulated eNOS S-glutathionylation, which can at
least partially explain the molecular mechanisms leading to eNOS un-
coupling in response to cLDL.
Several amino acids such as cysteine, histidine, and arginine are
known to inhibit carbamylation of albumin.29 Here, we observed
that cysteine, histidine, and arginine present during ex vivo carbamyla-
tion of LDL prevented cLDL-induced endothelial ROS production.
This indicates that dietary supplementation of these amino acids
may provide a potential treatment strategy to preclude cLDL-
induced endothelial dysfunction in patients with increased protein
carbamylation such as CKD.
Finally, in the clinical part of the study, we documented a significant
association between LDL-carbamyl-lysine levels and all-cause mor-
tality and cardiovascular events in patients with CKD. These findings
point to an important role of cLDL in the development of cardiovas-
cular disease in CKD patients and highlight cLDL as a novel cardiovas-
cular risk factor in these patients.
In summary, our data indicate that cLDL induces ED via activation
of the endothelial LOX-1 receptor leading to p38-dependent
NADPH-oxidase activation, ROS production, S-glutathionylation-
dependent eNOS uncoupling, and reduced NO bioavailability. In
addition, cLDL inhibits eNOS activation in a direct manner by affect-
ing eNOS phosphorylation (Figure 8). These findings represent a
novel pathomechanism of endothelial dysfunction potentially im-
portant for initiation of atherosclerotic vascular disease in patients
with CKD and in smokers, notably patient groups with a very high-
cardiovascular risk.
Supplementary material
Supplementary material is available at European Heart Journal online.
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